News

Around 1,800 patients will be enrolled from across 180 study centres globally in this randomized, double-blind, double-dummy, parallel group multicentre Phase III FULFIL trial. The trial is designed

Adocia’s HinsBet formulation incorporates BioChaperone technology which allows accelerated absorption of prandial insulins. The company said that the trial met its primary endpoint, measuring the increase of recombinant

Acelex has a new mode of action that specifically targets affected joints to relieve pain and restore mobility, while simultaneously preserving the integrity and safety of the gastrointestinal

The patent protects the improved modular design of EnWave’s nutraREV machinery, which is the most commercially advanced platform in the Company’s technology portfolio. EnWave has sold or received

Currently, the company is applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. The latest patent provides intellectual property rights in validated European countries through

Based on the results of this study (DRM04-HH02) and its first Phase 2b study (DRM04-HH01), Dermira plans to initiate a Phase 3 program for DRM04 in axillary hyperhidrosis

The conclusions remark that the patients treated with chondroitin sulfate achieved statistically significantly and clinically meaningful better pain and functional capacity scores. This drug also has improved safety

BREO ELLIPTA is a fixed dose combination of the inhaled corticosteroid, fluticasone furoate (FF) and the long-acting beta2 agonist (LABA), vilanterol (VI), administered using the ELLIPTA inhaler. The

Lucentis is a vascular endothelial growth factor (VEGF) inhibitor, designed to bind to and inhibit VEGF-A, a protein that is believed to play a major role in the